CAG
Crestwood Advisors Group Portfolio holdings
AUM
$5.58B
This Quarter Return
+3.51%
1 Year Return
+14.63%
3 Year Return
+71.56%
5 Year Return
+115.62%
10 Year Return
+272.08%
AUM
$1.03B
AUM Growth
+$1.03B
(+24%)
Cap. Flow
+$172M
Cap. Flow
% of AUM
16.62%
Top 10 Holdings %
Top 10 Hldgs %
29.34%
Holding
169
New
40
Increased
49
Reduced
53
Closed
5
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$19M |
| 2 |
Cognizant
CTSH
|
$11.3M |
| 3 |
iShares Biotechnology ETF
IBB
|
$4.57M |
| 4 |
iShares Core S&P 500 ETF
IVV
|
$3.81M |
| 5 |
Visa
V
|
$2.39M |
Top Sells
| 1 |
Target
TGT
|
$15.6M |
| 2 |
Union Pacific
UNP
|
$2.67M |
| 3 |
State Street
STT
|
$1.28M |
| 4 |
Medtronic
MDT
|
$1.1M |
| 5 |
iShares Morningstar US Equity ETF
ILCB
|
$945K |
Sector Composition
| 1 | Financials | 15.62% |
| 2 | Technology | 9.64% |
| 3 | Healthcare | 8.81% |
| 4 | Consumer Discretionary | 7.13% |
| 5 | Consumer Staples | 5.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Brookline Bancorp
BRKL
| $208K | 0.02% |
12,665
+1
| +0% | +$16 |
|
127
Oracle
ORCL
$628B
| $207K | 0.02% |
5,381
+195
| +4% | +$7.5K |
|
128
Lifecore Biomedical
LFCR
$288M
| $189K | 0.02% |
13,688
-1,980
| -13% | -$27.3K |
|
|
AGEN
129
Agenus
AGEN
$136M
| $136K | 0.01% |
32,928
| – | – |
|
130
Iovance Biotherapeutics
IOVA
$800M
| $87K | 0.01% |
+12,500
| New | +$87K |
|
131
Perspective Therapeutics
CATX
$251M
| $32K | ﹤0.01% |
54,824
| – | – |
|
|
SPRT
132
DELISTED
support.com, Inc.
SPRT
| $13K | ﹤0.01% |
15,000
| – | – |
|
|
PTN
133
DELISTED
Palatin Technologies
PTN
| $13K | ﹤0.01% |
+25,000
| New | +$13K |
|
|
CDMO
134
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $11K | ﹤0.01% |
35,000
| – | – |
|
|
UN
135
DELISTED
Unilever NV New York Registry Shares
UN
| – | – |
-4,912
| Closed | -$226K |
|
|
136
Target
TGT
$42B
| – | – |
-226,850
| Closed | -$15.6M |
|
137
Diageo
DEO
$61.1B
| – | – |
-1,725
| Closed | -$200K |
|
138
CVS Health
CVS
$93B
| – | – |
-4,464
| Closed | -$397K |
|
139
Bristol-Myers Squibb
BMY
$96.7B
| – | – |
-3,836
| Closed | -$207K |
|